Background: Mesenchymal stem cells (MSCs) attenuate injury in various lung injury models through paracrine effects. We hypothesized that intratracheal transplantation of allogenic MSCs could attenuate lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice, mediated by anti-inflammatory responses. Methods: Six-week-old male mice were randomized to either the control or the ALI group. ALI was induced by intratracheal LPS instillation. Four hours after LPS instillation, MSCs or phosphate-buffered saline was randomly intratracheally administered. Neutrophil count and protein concentration in bronchoalveolar lavage fluid (BALF); lung histology; levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and macrophage inflammatory protein-2; and the expression of proliferation cell nuclear antigen (PCNA), caspase-3, and caspase-9 were evaluated at 48 hours after injury. Results: Treatment with MSCs attenuated lung injury in ALI mice by decreasing protein level and neutrophil recruitment into the BALF and improving the histologic change. MSCs also decreased the protein levels of proinflammatory cytokines including IL-1β, IL-6, and TNF-α, but had little effect on the protein expression of PCNA, caspase-3, and caspase-9. Conclusions: Intratracheal injection of bone marrow-derived allogenic MSCs attenuates LPSinduced ALI via immunomodulatory effects.
INTRODUCTION
Though the management of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) has progressed, the mortality rate remains very high at 30%-50% [1] [2] [3] . Clinical research has shown that low tidal volume ventilation, the prone position, and extracorporeal membrane oxygenation significantly decrease the mortality rate [4] [5] [6] . Although ALI has various causes such as sepsis, pneumonia, pancreatitis, trauma, and burns [7, 8] , it is known that the common mechanism is the severe inflammatory injury to the endothelium and epithelium resulting in a compromised pulmonary barrier, which leads to permeability edema. A treatment goal can be the effective blockage of this common mechanism [9] . Inflammatory mediators such as cytokines, reactive oxygen species, leukotrienes, and products of complement activation increase in the bronchoalveolar lavage fluid (BALF) of a patient with ALI.
From a morphological point of view, the early stage of ALI shows an infiltration of neutrophils into the lung tissue. This transfer of neutrophils into the lung tissues is caused by neutrophil migrating factors such as neutrophil chemotactic factor and cytokines [10, 11] . Moreover, one study reported that when lipopolysaccharide (LPS) or tumor necrosis factor (TNF) is injected into a neutrophil-deficient animal, the lung damage decreases [11, 12] and is dependent on the functional changes of the neutrophil. These results suggest that preventing or reducing the infiltration of neutrophil can reduce ALI [13] .
Mesenchymal stem cells (MSCs) have multilineage differential flexibility that allows for differentiation in tissue damage [14] . Recent studies have suggested that bone marrow-derived multipotent MSCs may have therapeutic applications in several clinical disorders, including hepatic failure, sepsis, and myocardial infarction [15] [16] [17] [18] [19] . Because MSCs can differentiate into type I and II epithelial cells, vascular endothelial cells, and fibroblasts during lung injury [20, 21] , they have been studied in vivo in several animal models of lung diseases. However, the engraftment of MSCs into damaged tissue is rare. Recent studies have reported the therapeutic effect of MSCs through a paracrine mechanism by the modulation of cytokine or growth factor [16, 18, 22] . This study was performed to evaluate the anti-inflammatory effect of MSCs in an LPS-induced ALI model.
MATERIALS AND METHODS

Animals and Experimental Drugs
Six-week-old male C57BL/6 mice weighing 21-22 g (Daehan Bio Link, Eumseong, Korea) were divided into the four groups as follows: (1) the control group (CTL, n = 12), (2) the LPS only group (LPS, n = 12), (3) the MSCs only group (MSC, n = 6), and (4) the MSCs administration following LPS-induced ALI group (LPS/MSC, n = 9). LPS (Escherichia coli Serotype 055:B5; Sigma-Aldrich, St. Louis, MO, USA) powder was dissolved in a saline solution and 5 mg/kg was injected intratracheally to induce ALI [23] . Four hours after the injection of LPS, the mice were anesthetized and MSCs (7.5 × 10 5 cells in 30 µl of PBS) were injected into the trachea. Mice were killed 48 hours after the LPS injection [24] . We collected BALF for cell analysis and cytokine measurement and lung tissue for histology. To anesthetize the mice, ketamine at 70 mg/kg (Yuhan Pharma, Seoul, Korea) and xylazine hydrochloride at 9 mg/kg (Bayer Korea, Seoul, Korea) were used. All animals were cared for according to the guidelines of the Institutional Animal Care and Use Committee of Asan Medical Center (No. 2009-13-115).
KEY MESSAGES
■ Treatment with mesenchymal stem cells (MSCs) attenuated acute lung injury (ALI) by decreasing neutrophil recruitment into the bronchoalveolar lavage fluid and the protein levels of proinflammatory cytokines including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α.
■ The therapeutic effect of MSCs in the lipopolysaccharide-induced ALI model may be associated with an anti-inflammatory effect via immunomodulation.
Isolation and Administration of MSCs
Bone marrow-derived cells were isolated from the femur of 4-week old male C57BL/6 mice. Plastic-adherent MSCs were cultured as previously described, but with a slight modification. Bone marrow-derived cells were plated in plastic culture dishes (SPL Life Sciences, Pocheon, Korea) with complete media (Dulbecco's Modified Eagle's Medium containing 10% fetal bovine serum, penicillin, 100 mM sodium pyruvate, and streptomycin) and incubated at 37°C in a humidified atmosphere with 5% CO2. Two days later, unattached cells were removed by washing with complete media, which was replaced and changed once or twice per week. Fourth-passage MSCs were administered to the mice. Monoclonal antibodies, including CD34, CD45, CD73, and CD90 that were fluoresceinlabelled with fluorescein isothiocyanate or phycoerythrin, were used to confirm the purity of the MSCs [25] . CD34 and CD45 did not appear if it was positive for CD73 and CD90 (Supplementary Figure 1 ). Therefore, this study confirmed that the cultured cells maintain the characteristics of MSCs.
Measurement of Neutrophil Count and Protein Content in BALF
The protein content in the BALF was measured as per the Bradford's method. After a Diff-Quick stain, the number of neutrophils was measured using the method described by Everhart et al. [26] . Using a 400-times magnification optical microscope, 500 cells were counted to determine the proportion of neutrophils in the white blood cell population and calculate the number of neutrophils.
Measurement of Cytokines in BALF
TNF-α, interleukin (IL)-1β, IL-6, and macrophage inflammatory protein (MIP) were measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA).
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Myeloperoxidase Activity Assay
Myeloperoxidase (MPO) activity in the serum was measured using a MPO kit (R&D Systems).
Western Blot Analysis
The lung tissue was homogenized in a lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 1% NP-40, 2.5 mM sodium pyrophosphate, 1 mM-glycerophosphate, 1 mM Na3VO4, 2 mM p-nitrophenyl phosphate, and a protease inhibitor cocktail) on ice with a polytron tissue homogenizer (Brinkmann, Riverview, FL, USA). After centrifugation at 1,200 rpm for 10 minutes at 4°C, the proteins were separated in an 8% or 12% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes were blocked with 5% skim milk for 1 hour at room temperature and then incubated with the primary antibody (1:500 or 1:1,000) overnight at 4°C. After washing with 0.5% Tween-20 in Tris-buffered saline (50 mM Tris, 150 mM NaCl, pH 8.0), the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (1:5,000). Primary antibodies against the following proteins were used: caspase-3, caspase-9 (Cell Signaling Technology, Beverly, MA, USA), β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and proliferation cell nuclear antigen (PCNA; Abcam, Cambridge, MA, USA).
Histology Analysis
The severity of lung injury was determined using paraffin embedded-lung sections stained with hematoxylin & eosin. Ten sections per mouse were randomly chosen for the analysis.
Lung injury was scored according to the following four categories: alveolar congestion, hemorrhage, neutrophil infiltration into the airspace or interstitum, and neutrophil infiltration into vessel. Each category was graded on a four point scale (0-3) [27] . 
Growth Factor Measurement
The level of hepatocyte growth factor (HGF; EIAab, Wuhan, China) in BALF was measured via ELISA.
Statistical Analysis
All results are represented as mean and standard error of the mean. Mean values of different groups were analyzed using an independent-samples t-test. Successive data that do not follow normal distribution were analyzed using a Mann-Whitney U-test. Categorical data were analyzed using a chi-square test. All calculations were carried out using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) with a significance level set at P < 0.05.
RESULTS
Attenuation of LPS-induced ALI by MSCs
We investigated the total white blood cell count and neutrophil percentage of the BALF. The LPS group showed a significantly higher white blood cell count than the control group did (91.6± 9.7 × 10 4 /ml vs. 36.2 ± 2.9 × 10 4 /ml, P < 0.05) and was significantly decreased in the LPS/MSC group (58.9±4.4×10 4 /ml, P < 0.05) ( Figure 1A) . The percentage of neutrophils was significantly higher in the LPS group when compared to that of the control group (84.1% ± 1.7% vs. 1.7% ± 1.0%, P < 0.05) and lower in the LPS/MSC group when compared that of the LPS group (70.4%± 2.3%, P < 0.05) ( Figure 1B) . Protein concentration in the BALF significantly increased in the LPS group when compared to that of the control group (0.69±0.09 mg/ml vs. 0.20±0.02 mg/ml; P < 0.05). However, the LPS/MSC group did not have a significant decrease in protein concentration when compared to that of the LPS group (0.49 ± 0.05 mg/ml; P > 0.05) ( Figure 1C ). LPS/MSC group significantly attenuated MPO activity (an indication of neutrophil accumulation) in serum when compared to that of the LPS group (11,354 ± 551.9 pg/ml vs. 17,139 ± 973.6 pg/ml, P < 0.05) ( Figure 1D ).
On histological analysis, the CTL (Figure 2A and B) and MSC ( Figure 2C and D) groups also had normal parenchymal architecture without any exudates or edema. The LPS group showed an infiltration of inflammatory cells, mainly polymorphonuclear cells, into the alveolar space and interstitium. In addition, there was hemorrhage in the alveolar space ( Figure 2E and F). However, the LPS/MSC group had a relatively wellmaintained alveolar space compared to that of the LPS group. 2G and H). To quantify the differences, lung injury was scored ( Figure 3 ). LPS groups showed significant increases in lung injury score scores (P < 0.05, vs. CTL groups). LPS/MSC groups significantly attenuated the LPS-induced increases in injury scores (P < 0.05, vs. LPS groups).
Anti-inflammatory Effect of MSCs in LPS-induced ALI
The Figure 4D ).
Cell Proliferation and Apoptosis
Western blot analysis showed that the expression of PCNA and caspase-3 increased in the LPS group. MSC treatment attenuated the expression of PCNA, but showed no significant changes in caspase-3 and caspase-9 ( Figure 5 ).
Growth Factor
HGF levels in the BALF were higher in the LPS group compared to those in the CTL group (378.9 ± 108.1 pg/ml vs. 54.7 ± 14.3 pg/ml, P < 0.05). However, HGF levels did not significantly change in the LPS/MSC group (255.4 ± 86.5 pg/ml).
DISCUSSION
In this study, we evaluated the early effect of allogenic MSCs in an LPS-induced ALI animal model by analyzing various inflammatory mediators, proliferation markers, markers of apoptosis, and histological changes. We showed that the injection of MSCs decreased the infiltration of neutrophils and early inflammatory cytokines including TNF-α, IL-1β, and IL-6, but showed no effect on apoptosis and the regulation of HGF. The therapeutic effect of MSCs is considered an anti-inflammatory effect of MSCs in early stage of ALI.
The pathophysiology of ALI is a physiological inflammatory response that causes extensive damage to the alveolar-capillary membrane through the actions of alveolar macrophages, neutrophils, platelets, TNF-α, proteases, arachidonic acid metabolites, and oxygen radicals [28] . Sepsis-induced ALI is caused by the interaction of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, derived from neutrophils, alveolar macro-phages, and vascular endothelial cells activated by endotoxin [29] . When LPS is injected into mice, inflammation can be noticed after 4-5 hours [30] . Therefore, MSCs were injected 4 hours after LPS injection in our model. LPS induces the infiltration of neutrophils from the blood into the alveoli, which simultaneously damages the first and second alveoli and vascular endothelial cells, thus destroying the epithelial and vascular barriers, causing alveolar flooding [23] . In LPS-induced ALI, cytokines are signaling molecules that play an important role in starting, amplifying, and sustaining an inflammatory reaction. Proinflammatory cytokines, such as TNF-α and IL-1β, appear in the early stage of lung injury and are known to aggravate the inflammatory reaction by inducing the secretion of chemokines and immunomodulators. High concentrations of those cytokines are observed in the BALF of a patient with ARDS or at high risk for ARDS [31, 32] . IL-6 is produced by an activated macrophage; it stimulates acute inflammation. IL-6 concentration is highly elevated in the BALF of patients who are at high risk of an ALI. The high concentration is maintained until the ALI is confirmed. After injecting IL-1β in vivo and in vitro, a cytokine-induced neutrophil chemotactic factor is produced and detached. This induces the inflow of active neutrophils into the alveoli [33] . Therefore, in this study, TNF-α, IL-1β, and IL-6 levels were measured to assess the effect of MSC injection on the relevance of cytokines in LPS-induced ALI.
MIP is an inflammatory mediator, which is produced from various cells, such as macrophages, polymorphonuclear cells, T cells, eosinophils, basophils, and platelets, that induces local inflammatory reaction as it quickly attracts neutrophils [34] . This study showed that the concentration of MIP-2 in BALF did not decrease with the MSC injection.
Both proliferation and cell death were activated in LPS-in- duced ALI. MSCs partially suppressed proliferation, but had no effect on cell death. The conquest to cure incurable diseases using stem cells has arose as an important issue in regeneration medicine and has been applied in almost every field of medicine, including cardiology, neurology, hematology, immunology, genetics, pulmonology, hepatology, and in bone, cartilage, and skin diseases. Even though the positive effects of MSCs are reported for various diseases, the mechanism of treatment has not been proved. In addition, the therapeutic effect differs depending on the stem cell type and number and the injection route, time, and number. In our study, we focused on the early therapeutic effect of allogenic bone marrow-derived MSCs in an LPS-induced ALI animal model. Though MSCs attenuated the LPS-induced ALI through decreasing neutrophils and inflammatory factors, it had little effects on cell death and growth hormone in the early stage. Our findings suggest that allogenic MSCs are still a promising clinical therapeutic modality, but the mechanism and safety of MSCs have not been established. 
